Carboxylic acids, e.g. valproic acid (A61K31/19)

ethod for increase of organism resistance to combined toxic action of nanoparticles of copper, zinc and lead oxides // 2642674
FIELD: medicine.SUBSTANCE: method for reduction of the adverse effects of combined effects of copper (CuO), zinc (ZnO) and lead (PbO) oxides nanoparticles on organism in risk groups covering individuals exposed to such effects under production conditions. Method includes prescription of a complex of biologically active drugs: glutaminic acid, glycine, N-acetylcysteine, pectin enterosorbent, fish oil preparation rich in unesterified omega-3 fatty acids, Vitamins A, C, D3, E, selenium, iron and iodized preparations. This complex is taken by repeated courses 1-2 times a year for 4-6 weeks daily at doses providing daily intake of 300 mg of glycine, 600 mg of cysteine, 4 g of glutaminic acid, 25 ml of fish oil with 12-15% content of polyunsaturated omega-3 fatty acids, 4-5 grams of pectin, as well as selenium, iron, iodine and these vitamins in doses that provide the normal physiological needs of the organism.EFFECT: reduction of all three metals in the blood, improved elimination function of the liver and kidneys, reduced integral signs of chronic intoxication, including signs of neurotoxicity, and genotoxic combined action of copper, zinc and lead oxides nanoparticles on the body.6 tbl
Composition for increasing operability and physical durability // 2642673
FIELD: food industry; pharmaceutical industry.SUBSTANCE: invention relates to the pharmaceutical and food industries and is a composition for improving working capacity and physical endurance comprising vitamin A, vitamin E and succinic acid, characterized in that it further comprises dry guarana extract and a chocolate mass, the components in the composition being in a certain ratio, in mass %.EFFECT: invention provides good taste qualities, a convenient form for reception, and also provides for a short time increase in efficiency and physical endurance by taking a complex of active substances optimally selected and in an amount sufficient to achieve maximum effect.1 cl, 3 ex, 2 tbl

Concentrated therapeutic phospholipide compositions // 2642653
FIELD: pharmacology.SUBSTANCE: composition for treatment or prevention of cardiometabolic disorders, a metabolic syndrome, neurodegenerative disorders comprises a concentrated therapeutic phospholipid extract comprising compounds of Formula I wherein the total amount of the phospholipid compounds of Formula I from the extract is in a concentration of 60 wt % to 90 wt % of the total weight of the composition and the extract includes astaxanthin; to a capsule containing a concentrated therapeutic extract of krill oil that contains the phospholipid compounds of Formula I and the extract includes astaxanthin; to application of a composition that includes a concentrated therapeutic phospholipid extract containing compounds of Formula I for preparation of therapeutic compositions for serum triglyceride levels lowering; to application of a concentrated therapeutic phospholipid extract that contains compounds of Formula I for preparation of pharmaceutical compositions for treatment of cardiovascular diseases.EFFECT: increased mass percentage of phospholipids in the composition.20 cl, 35 dwg, 2 tbl, 7 ex
Complexes based on chondroitin for cutaneous absorption // 2642612
FIELD: pharmacology.SUBSTANCE: invention is a transdermal delivery composition comprising non-covalent complexes between non-sulphated chondroitin having a molecular weight of 5 to 100 kDa determined by exclusion chromatography and active ingredients selected from diclofenac or its salts and ketorolac or its salts.EFFECT: invention provides passage through the stratum corneum of the skin, penetration into the epidermis, through the mucous membrane, as well as delayed release of the active components.4 cl, 11 tbl, 7 ex

ethod of producing l-arginine nanocapsules // 2642233
FIELD: nanotechnologies.SUBSTANCE: invention relates to nanotechnology, namely to the method of producing L-arginine nanocapsules in sodium carboxymethyl cellulose. Method is characterized in that L-arginine is slowly added to the suspension of sodium carboxymethyl cellulose in methanol in the presence of 1 % of E472c preparation as a surfactant with stirring at 1,000 rpm, then 10 ml of petroleum ether is added, obtained suspension is filtered and dried at room temperature, the core/shell weight ratio being 1:1 or 1:3, or 5:1. Method ensures the simplification and acceleration of the process of producing nanocapsules, reduction in losses in the production of nanocapsules, and can be used in the food industry.EFFECT: method ensures the simplification and acceleration of the process of producing nanocapsules, reduction in losses in the production of nanocapsules, and can be used in the food industry.1 cl, 2 dwg, 4 ex
N-acetyl-l-cysteine for application in extracorporeal fertilization // 2641606
FIELD: pharmacology.SUBSTANCE: invention is a pharmaceutical composition containing N-acetyl-L-cysteine (NAC) alone or together with (2) selenium in the form of selenomethionine and/or (3) melatonin and/or their physiologically acceptable salts and a suitable carrier or an excipient for application in IVF treatment of infertility in a mammal, characterized by a NAC dose of 50-150 mg/kg of body weight administered intravenously or a NAC dose of 30-45 mg/kg of body weight is administered once daily for 1 to 3 days orally, or alternatively, 600 mg of NAC is administered three times a day orally for three consecutive days in a week, followed by four days without drug administration for a total of three months or more before IVF-treatment.EFFECT: higher percentage of live births.1 tbl, 12 cl, 1 dwg

ethod for inguinal hernia treatment // 2641368
FIELD: medicine.SUBSTANCE: in the medial part of the patient's inguinal canal lying on the back, a polymerizable mixture consisting of three solutions A, B and C is introduced by injection through the needle. Solution A is a solution of a copolymer of acrylamide and hydroxysuccinimide ester of acrylic acid. Solution B is a solution of 1,4-butanediamine and succinic acid. Solution C is a solution of sodium hydrogencarbonate. The molar ratio of acrylamide and hydroxysuccinimide ester of acrylic acid in the copolymer is selected in the range of 9:1 to 7:3, the molar ratio of 1,4-butanediamine to succinic acid in solution B is selected in the range of 4:1 to 1:1. The concentration of solution A was selected from the mass concentration of the copolymer in solution A in the range 21.8-26.3 g/l. The concentration of solution B is: for 1,4-butanediamine - about 22.0 g/l, for succinic acid - in the range of 7.4-29.5 g/l. The concentration of solution C is in the range of 0.6-1.1 mol/l. The ratio of the quantity of solutions A and B is chosen so that the molar ratio of hydroxysuccinimide ester of acrylic acid in the copolymer and 1,4-butanediamine does not exceed 2:1. The ratio of the quantity of solutions B and C is selected from the condition that the molar ratio of sodium hydrogencarbonate and succinic acid is not less than 2:1. The mixture is prepared by successively mixing solutions A and B and then solution C. Then, the prepared mixture is injected until the inguinal canal is filled and the patient is left in the indicated position until the polymerization of the mixture introduced into the inguinal channel is completed.EFFECT: invention allows minimally invasive elimination of hernial protrusion, reliable closure of hernial gates, and prevention of recurrent inguinal hernia.7 cl, 9 dwg
Agent for pyoinflammatory processes in soft tissues and mucous membranes // 2641095
FIELD: pharmacology.SUBSTANCE: invention is an agent for treatment of pyoinflammatory processes in soft tissues and mucous membranes in the form of a film that contains benzalkonium chloride, metronidazole, lidocaine hydrochloride, dimethyl sulfoxide, glycerol, sodium salt of carboxymethylcellulose and 5% solution of aminocaproic acid, with components in the agent being in a specific ratio of mass fractions.EFFECT: creation of an effective agent in the form of a film possessing antimicrobial, sorption, analgesic, wound healing and haemostatic action.4 tbl
Application of fullerene c60 aqueous solution as therapeutic agent at atopic dermatitis disease // 2641091
FIELD: pharmacology.SUBSTANCE: invention is application of a therapeutic agent for parenteral administration in atopic dermatitis, which is a water-salt solution consisting of fullerene C60, pluronic F-127 and physiological saline, where the components in the agent are in a certain ratio per ml of solution.EFFECT: reduction of allergic inflammation, skin regeneration improvement.1 tbl, 5 dwg
eans for topical application in complex therapy of oral cavity diseases // 2641056
FIELD: pharmacology.SUBSTANCE: topical means for complex treatment of oral cavity diseases contains ground succinic acid introduced into the oil extract of propolis by suspension type in a weight ratio of 0.5:99.5; while the oil extract of propolis is prepared by extraction of propolis raw frozen at -10°C and ground to a powdered state with a fraction size of 0.05-0.1 mm with sunflower oil refined at room temperature for 5 days at a propolis to extractant ratio of 1:9.EFFECT: means has a strong antioxidant effect, contains no alcohol and irritants, so can be used for application to mucous membranes of the oral cavity in treatment of individuals sensitive to alcohol, or children.2 tbl
icroelement preparation for animals // 2640908
FIELD: agriculture.SUBSTANCE: preparation comprises 2Na- or 2K-salt of ethylenediamine-N,N1-disuccinic acid in an amount of 20.0-50.0 wt %; Na- or K-salt of an amino acid or an amino acid in an amount of 3.0-15.0 wt %; iron (III) in an amount of 0.3-3.0 wt %; magnesium (II) in an amount of 0.3-3.0 wt %; manganese (II) in an amount of 0.4-2.5 wt %; copper (II) in an amount of 0.05-0.25 wt %; zinc (II) in an amount of 0.3-2.5 wt %; cobalt (II) in an amount of 0.005-0.05 wt %; selenium (IV) in an amount of 0.01-0.03 wt %; iodine (I) in an amount of 0.03-0.08 wt %; water - the rest.EFFECT: invention provides a high efficiency of the application of the claimed preparation for the prevention and treatment of chronic intoxication with heavy metals.2 cl, 5 tbl, 4 ex

Therapeutic application of compounds // 2640596
FIELD: pharmacology.SUBSTANCE: invention refers to the application of a compound of formula R1-COOH (I), where R1 is an alkyl group with a main chain of 7-11 carbon atoms, possibly branched in any position of the carbon atom in the main chain, where branching is a side C1-6 alkyl group. The alkyl group of the main chain and/or the side alkyl groups optionally contain one or more heteroatoms. The specified compound is selected from 4-ethyl octanoic acid, 2-butyl octanoic acid, 4-methyl nonanoic acid and 3-methyl undecanoic acid or its pharmaceutically acceptable salt, amide or ester, for treatment or prevention of disease or biomedical state, selected from disorders associated with cramps.EFFECT: increased efficiency of the composition and treatment method.2 cl, 9 dwg, 3 tbl
Systems and compositions for postprocedure skin care and methods of application thereof // 2640504
FIELD: pharmacology.SUBSTANCE: invention is a topically-applied wound healing composition consisting of the following components: aluminium sulfate tetradecahydrate present in an amount from about 40.0 wt % to about 55.0 wt % on the basis of the weight of the topically-applied wound healing composition, calcium acetate monohydrate present in an amount from about 28.0 wt % to about 39.0 wt % on the basis of the weight of the topically-applied wound healing composition, common oat grain protein present in an amount from about 0.01 wt % to about 20 wt % on the basis of the weight of the topically-applied wound healing composition, soy protein in an amount from about 0.01 wt % to about 20 wt % on the basis of the weight of the topically-applied wound healing composition, whey protein present in an amount from about 0.01 wt % to about 20 wt % on the basis of the weight of the topically-applied wound healing composition, chitosan present in an amount from about 0.25 wt % to about 50 wt % on the basis of the weight of the topically-applied wound healing composition, potassium sorbate present in an amount from about 0.25 wt % to about 10 wt % on the basis of the weight of the topically-applied wound healing composition and dextrin present in an amount from about 5 wt % to about 50 wt % on the basis of the weight of the topically-applied wound healing composition.EFFECT: effective healing of postprocedure wounds on the skin, high stability.23 cl, 4 dwg, 8 tbl, 4 ex

Cystathionine-g-lyase (cse) inhibitors // 2640418
FIELD: pharmacology.SUBSTANCE: invention relates to compounds of the Formula (I) or their pharmaceutically acceptable salts inhibiting the activity of cystathionine-gamma-lyase (CSE). In Formula (I) A is or -CONHSO2R4, where R4 is independently unsubstituted alkyl or unsubstituted aryl; X is CR1 or N; R1 is H; each R2 and R3 is H. The invention also relates to a pharmaceutical composition comprising the said compounds and a method for treatment or prevention of various diseases associated with CSE activity.EFFECT: increased efficiency of the composition and treatment method.13 cl, 11 dwg, 2 tbl, 17 ex
Bicyclic compound // 2640416
FIELD: pharmacology.SUBSTANCE: in the general formula (1) (1), A is an unbranched C1-C3 alkylene group, wherein one methylene group is optionally substituted with O or S; n is an integer from 3 to 5; each of X1 and X2 is independently CH or N; each of W1 and W2 is independently a carboxyl group or W1 is a carboxyl group and W2 is a tetrazolyl group; V is a linear or branched C1-C8 alkylene group in which one methylene group is optionally substituted by O or S; R is a group selected from the following , , where R1, R2, R3, R4 and R5 is a hydrogen atom, a halogen atom, a C1-C6 alkyl group which may have a substituent group, a C1-C6 alkoxy group, a C3-C6 cycloalkyl group, a C3-C6 cycloalkoxy group, a halogen C1-C4 alkyl group, a halogen C1-C4 vinyl group which may have a substituent group, an ethynyl group which may have a substituent group, a phenyl group which may have a substituent group on the aromatic ring, a phenoxy group which may have a substituent group on the aromatic ring, a benzyl group, which may have a substituent group on the benzene ring, a phenethyl group which may have a substituent group on the benzene ring, a benzyloxy group which may have a substituent group on the benzene ring, a benzylsulfanyl group which may have a substituent group on the benzene ring, a benzylamino group which may have a substituent group on the benzene ring, a phenyloxymethyl group which may have a substituent group on the benzene ring, a phenylsulfanylmethyl group which may contain a substituent group on the benzene ring, or a phenylaminomethyl group which may have a substituent group on the benzene ring, wherein the substituent group is indicated in the claims, m is an integer of 1 or 2 and each of Y1 and Y2 independently represents methylene, O or S, provided that they both do not represent S.EFFECT: compounds can be used to prevent or treat disorders associated with soluble guanylate cyclase, such as hypertension, pulmonary hypertension, heart failure, endothelial dysfunction, atherosclerosis, peripheral vascular disease, angina pectoris, thrombosis, myocardial infarction, erectile dysfunction or impaired renal function.9 cl, 41 tbl, 213 ex
ethod for differential organ preservation treatment of cervical pregnancy and pregnancy in uterine scar after caesarean section, depending on data of integrated ultrasound and levels of human chorionic gonadotropin (versions) // 2640191
FIELD: medicine.SUBSTANCE: after emergency hospitalization, bilateral embolization of the uterine arteries (UAE) is performed, including methotrexate administration of in the amount of 50 mg endoarterially in the presence of ultrasound signs of chorion infiltration with formation of vascular malformation and HCG level increase. The gestational sac is left. 3 days after, ultrasound and HCG control is performed. With a HCG decrease in by at least 25% and no visualization of blood flow in the chorion with ultrasound and colour Doppler mapping (CDM), the patient is released for outpatient monitoring. With blood flow persistence in the chorion, UAE is repeated with a search for these vessels. If there is insufficient decrease in the blood plasma HCG, the patient receives methotrexate into the gestational sac cavity in an amount of 2-10 mg. In the absence of ultrasound signs of chorionic growth, the gestational sac is removed simultaneously under the control of ultrasound. In the absence of bleeding and normal data of the control ultrasound after 1 day, the patient is released for outpatient monitoring. In the presence of ultrasound signs of chorionic ingrowth and decreasing level of HCG, UAE without endoarterial administration of methotrexate is performed. 3 days after, ultrasound and HCG control are performed. With a HCG decrease in by at least 10% and no visualization of blood flow in the chorion with ultrasound and CDM, the patient is released for outpatient monitoring.EFFECT: maintaining the uterus integrity and its reproductive function while reducing the duration of hospitalization.4 cl, 5 ex
Energy drink // 2639493
FIELD: pharmacology.SUBSTANCE: invention is an energy drink, intended for enteral nutrition of children, made in the form of sterile solution, comprising glucose, ethanol, 0.3-0.5% hydrogen peroxide, citric acid, prepared water for injection containing oxygen under overpressure of 0.2 atm at +8°C. Components in the drink are in a specific ratio in wt %.EFFECT: at introduction into the stomach of a child in a state of lung-heart, digestive and thermal failure in a deafened state of consciousness, invention provides increase in body temperature, elimination of acrocyanosis, heaviness and pain in the right under-rib space, deafening, confusion, increase in the functional activity of the central nervous system and improved mood.1 cl
ethod for feeding of infants with mucoviscidosis // 2639450
FIELD: medicine.SUBSTANCE: dry milk product "Pre Nutrilak" is used, in which a portion of water needed for mixture dilution in standard concentration, is replaced with a saline solution of 0.9% sodium chloride, the amount of which depends on the air temperature in the room and the body weight of the child. At the air temperature of 20°C and child weight of up to 5 kg, 60 ml of physiological saline is required to dilute the required amount of dry mixture,10 kg - 90 ml of physiological solution, at the temperature of 25°C and child weight of up to 5 kg - 170 ml of physiological solution, at the child weight of 5-10 kg - 230 ml of physiological solution, at the temperature of 30°C and child weight of up to 5 kg - 280 ml of physiological solution, and at the child weight of 5-10 kg - 450 ml of physiological solution, with feeding frequency of is 7-10 times a day.EFFECT: method allows to provide the necessary daily dose of sodium chloride and to adapt the therapeutic diet of infants with mucoviscidosis.4 tbl, 2 ex
ethod for treatment of heavy liver lesion with posttraumatic coagulopathy // 2639422
FIELD: medicine.SUBSTANCE: right gastro-omental vein is excised and catheterized, through which fresh frozen plasma and platelet concentrate in a ratio of 1:1 or fresh platelet-rich plasma is transfused into the portal vein system with additional administration of 1 g tranexamic acid for 10 minutes and further administration every 8 hours for 1 g till hyperfibrinolysis reduction. Treatment is carried out under the control of thromboelastography, aggregation, APTT, PT, MHO and fibrinogen level.EFFECT: method allows to achieve maximum hemostatic effect in the wound, to correct the key pathogenetic links of post-traumatic coagulopathy and to reduce the risk of early and distant complications.1 cl
ethod for endothelioprotection in adma-similar gestosis model by arginase ii inhibitor // 2639415
FIELD: pharmacology.SUBSTANCE: method involves reproduction of gestosis in laboratory pregnant Wistar rats by daily intraperitoneal administration of the NO-synthase inhibitor L-NAME from day 14 to day 20 of pregnancy at a dose of 25 mg/kg/day. At that, correction of endothelial dysfunction is performed daily by intragastric administration of a selective inhibitor of arginase II-KUD975. Inhibitor administration is performed 30 minutes prior to the administration of L-NAME at a dose of 1 mg/kg of animal body weight.EFFECT: pronounced correction of dysfunction under the conditions of specific mechanisms of the pathological process in pregnant women, with elimination of side effects typical for low- and nonselective arginase inhibitors.1 ex
Hemostatic coating in form of sponge or film (versions) // 2639379
FIELD: pharmacology.SUBSTANCE: invention is a hemostatic coating in the form of a sponge or film containing a base and an active substance zeolite, characterized by containing sodium alginate, a plasticizer and water as the base, and natural zeolite (Na2+, K2+)O⋅Al2O3⋅8SiO2⋅10H2O as an active substance, and the components in the hemostatic coating are in a certain ratio, in wt %.EFFECT: expanded assortment of hemostatic sponges and films with pronounced hemostatic action and a significant decrease in the temperature of tissues at the place of agent contact with the wound surface.4 cl, 25 ex
ethod for prevention and treatment of physical development violations in children associated with complex low-level habitat pollution by lead, manganese, nickel, chromium and cadmium // 2639124
FIELD: medicine.SUBSTANCE: "Pantogam" preparation is introduced orally 15-20 minutes after eating, in an age-defined dosage rate for 21 days; "Multi-tabs Junior", 1 pill once a day for 21 days; "Reamberin" intravenously dropwise: 5 to 10 years - 200 ml once a day, 11 to 15 years - 400 ml once a day, in an amount of 5-7 injections daily or every other day for 7 days; "Eslidin" 1 capsule twice a day before meals in the morning and evening for 21 days; "Enterosgel" 1.5-2 h before or 2 hours after meals or after taking medicines, for children aged 5 to 10 years - 15 g twice a day, 11 to 15 years- 15 g 3 times a day, course lasts 7 days. Physiotherapy is also used in the form of TNF-therapy, therapeutic exercises, respiratory gymnastics and conditioning procedures. Treatment and prevention are conducted twice a year by courses of 21 days.EFFECT: increased efficiency of treatment.5 cl, 7 tbl
Topical application compositions containing dapson and dapsone/adapalen, and methods for their application // 2638815
FIELD: pharmacology.SUBSTANCE: invention is a dermatological composition containing dapsone, the first solubilising agent, which is monoethyl ether diethylene glycol, polymer thickener and water, where dapsone is present in the composition at a concentration of 3 wt % to 10 wt % and the polymer thickener consists of a acrylamide/sodium acryloyldimethyltaurate copolymer.EFFECT: reduced particle size of dapsone, which leads to minimized feeling of the presence of sand when applied, and decreased dapsone dissolution in the monoethyl ether of diethylene glycol that leads to a more aesthetic appearance of the composition.19 cl, 3 dwg, 8 tbl, 6 ex
ethod of producing complex acid salts of divalent metals of dicarboxylic acids // 2638157
FIELD: chemistry.SUBSTANCE: method of producing complex acid salts of divalent metal dicarboxylic acids of general formula: Me(AcH)2⋅nH2O, where Me is a divalent metal atom, Ac is an anion of the dicarboxylic acid, H is hydrogen, n is 0-8, is carried out by neutralisation in an aqueous medium, with an oxide of the general formula MeO, where Me is a divalent metal atom, where high, more than 95 wt %, purity of the final product is provided by the molar concentration of the dicarboxylic acid and the divalent metal oxide in the aqueous solution in a ratio of 2.005 to 2.1:1. The synthesis is carried out in such a way that a constant, equal to the original, ratio between all components of the reaction is maintained in the reaction volume. Suitable acids are succinic, fumaric, L-aspartic, L,D-aspartic acids, and as oxides - calcium oxide, magnesium oxide, zinc oxide.EFFECT: improved method.7 cl, 8 ex
Enantiomers-2-hydroxy-derivatives of fatty acids // 2637937
FIELD: pharmacology.SUBSTANCE: invention relates to the enantiomer [-] of the formula: [-]NaOOC-HOCH-(CH2)6-(CH=CH-CH2)1-(CH2)6-CH3 and a pharmaceutical composition for treatment of a pathology caused by an abnormally low level of sphingomyelin and/or an abnormally high level of dihydrofolate reductase (DGFR) containing a therapeutically effective amount of an enantiomer of the following formula: [-]HOOC-HOCH-(CH2)6-(CH=CH-CH2)1-(CH2)6-CH3 and/or at least one of its pharmaceutically acceptable salts and, optionally, a pharmaceutically acceptable carrier. The invention also relates to a method for treatment of pathologies, the common etiology of which is an abnormally low level of sphingomyelin, and/or an abnormally low level of glycophelial acid protein (GPAP) and/or an abnormally high level of dihydrofolate reductase (DHFR), comprising administration of a therapeutically effective amount of the enantiomer of the following formula: [-]HOOC-HOCH-(CH2)6-(CH=CH-CH2)1-(CH2)6-CH3 and/or at least one of its pharmaceutically acceptable salts or composition comprising the said enantiomer and/or at least one of its pharmaceutically acceptable salts to the patient.EFFECT: increased efficiency of treatment.9 cl, 10 dwg, 5 tbl, 9 ex

System for dosed distribution // 2637420
FIELD: medicine.SUBSTANCE: systems and methods for controlled dosage of a composition comprising sodium diclofenac contained in a dispensing distribution system are provided. The method includes pressing of a manual pump to dispense a dose of a topical anaesthetic in a viscous solution where the manual pump is configured to dispense a dose within the tolerance indicated by the appropriate instruction approved by the government regulatory authority and topical solution distribution over the skin.EFFECT: systems and method allow to treat the signs and symptoms of osteoarthritis.12 cl, 5 dwg, 6 tbl, 4 ex

Retinoid-containing compounds for local application of "oil in water" emulsion type // 2637408
FIELD: medicine.SUBSTANCE: invention relates to a composition in the form of an oil-in-water emulsion, preferably not containing an emulsifier and containing at least one particular retinoid in a physiologically acceptable medium. A method for preparation of such composition and its application in cosmetics and dermatology is described.EFFECT: compositions are stable and well tolerated by patients.17 cl, 3 dwg, 1 tbl, 4 ex

Compounds for remyelination blockade treatment in diseases related to expression of herv-w shell protein // 2636355
FIELD: pharmacology.SUBSTANCE: this composition comprises an anti-MSRV/HERV-W Env ligand and at least one nitric oxide inhibiting drug, the said ligand comprising each of the complementarity determining regions (CDRs) specified in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, and the said NO inhibitor drug is selected from the group consisting of NG-Nitro-L-arginine methyl ester (L-NAME), S-methyl isothiourea (SMT), fumaric acid and dimethyl fumarate (DMF).EFFECT: presented inventions can be used to treat remyelination blockade in diseases associated with the expression of the HERV-W envelope protein.6 cl, 31 dwg, 3 ex

Anti-vegf/dll4-immunoglobulins with double variable domains and their application // 2636043
FIELD: biotechnology.SUBSTANCE: this protein comprises the first and the second polypeptide chains, each having two variable domains linked by a linker. This invention also relates to compositions comprising this binding protein. The compositions of the invention are intended for treatment of a disease characterized by excessive vascular growth, edema or abnormal expression or activity of DLL4 and/or VEGF. The invention also relates to binding protein application in the manufacture of a drug for treatment of this disease.EFFECT: invention allows preparation of compositions for treatment of a disease characterized by excessive vascular growth, edema or abnormal expression, or DLL4 or VEGF activity.26 cl, 1 dwg, 36 tbl, 15 ex
Polymeric water-soluble derivatives of 4-phenylbutanoic acid having anti-tumour activity // 2635539
FIELD: pharmacology.SUBSTANCE: invention relates to polymeric water-soluble derivatives of 4-phenylbutanoic acid having antitumour activity based on copolymers of N-vinylpyrrolidone or N-methyl-N-vinylacetamide with N,N-dimethylaminoethyl methacrylate and/or its quaternary ammonium salt of the general formula: .At that, k=60-75 moll. %, l=0-17 moll. %, m=2-39 moll. %, n=0-8 moll. %.EFFECT: new polymeric derivatives of 4-phenylbutanoic acid are characterized by good tolerability and high antitumour efficacy.3 tbl, 10 ex

Cosmetic cream // 2635524
FIELD: cosmetology.SUBSTANCE: invention is a cosmetic cream with an anti-inflammatory and anti-acne action comprising a mixture of ceteareth-6 and stearyl alcohol, stearic acid, triethanolamine, caprylic/caproic triglyceride, glycerol, perfume and water, further comprising an aqueous dioscore extract, a combination of plant oils, namely grape seed oil and coconut oil, and as a perfume - a composition of essential oils, and the components in the cream are in a certain ratio, in wt %.EFFECT: invention provides antimicrobial activity and a decrease in the appearance of acne, an expansion of the arsenal of agents with an anti-inflammatory and regenerative effect.1 dwg, 3 tbl, 1 ex

Stable anti-inflammatory solutions for injection // 2635521
FIELD: pharmacology.SUBSTANCE: liquid pharmaceutical solution for injection contains ketoprofen, amitriptyline, oxymetazoline, polyol, Na citrate and water. The polyol is selected from polyethylene glycol, propylene glycol, glycofurol and diethylene glycol monomethyl ether. The pharmaceutical solution has a pH of 4.5 to 7.0.EFFECT: injection solution of the invention is stable for 6 months when stored at a temperature between 2 and 30 degrees.11 cl, 7 dwg, 3 tbl, 8 ex

Compositions and methods for treatment of chronic inflammation and inflammatory diseases // 2635188
FIELD: pharmacology.SUBSTANCE: group of inventions refers to an oral pharmaceutical composition with anti-inflammatory activity, to a method for preparation of the said composition, to application of an oral pharmaceutical composition for manufacture of a medicament for treatment of chronic inflammation, to application of an oral pharmaceutical composition for treatment of chronic inflammation, and to a method for treatment of an individual with chronic inflammation. The pharmaceutical composition comprises: a) a non-steroidal anti-inflammatory drug (NSAID), which is a propionic acid derivative that has a log P value greater than 2.0; b) 0.01-15 vol. % of a pharmaceutically acceptable solvent, wherein the solvent is a pharmaceutically acceptable liquid polyethylene glycol polymer; and c) at least 50 vol. % of a pharmaceutically acceptable hydrophobic lipid adjuvant, wherein the pharmaceutically acceptable hydrophobic lipid adjuvant consists of a fatty acid triglyceride, a fatty acid diglyceride and a fatty acid monoglyceride, wherein the pharmaceutical composition is prepared so as to be in a solid state at a temperature of 15°C or lower and has a melting point of 25°C or higher.EFFECT: group of inventions allows the delivery of a therapeutic chemical compound with anti-inflammatory activity so that it more effectively inhibits the anti-inflammatory response, which ultimately increases the effectiveness of chronic inflammation treatment.16 cl, 4 dwg, 7 tbl, 10 ex
ethod for enhancing level of work capacity of laboratory animals in experiment // 2634373
FIELD: medicine.SUBSTANCE: one hour before conducting Porsolt's tests and the vertical screen-grid animals are orally given a solution voluntarily using a pipette containing 4 g of creatine monohydrate and 5 g of honey per 100 ml of distilled water, at a dose of 5 ml per 1 kg of body weight.EFFECT: expansing the arsenal of means of actoprotective action while minimizing the pain and suffering of laboratory animals in experiment.2 tbl, 2 ex
ethod for immune response stimulation and preparation for its implementation // 2634247
FIELD: pharmacology.SUBSTANCE: preparation includes an adjuvant and an inactivated antigenic material, with fatty (C12-C22) acid and fatty (C12-C22) acid N,N-dimethylaminopropylamide mixture in an 1:1 molar ratio used as an adjuvant, and the preparation includes the following components (wt %): a mixture of a fatty (C12-C22) acid and fatty (C12-C22) acid N,N-dimethylaminopropylamide (in a molar ratio of 1:1) to 0.01-10; aqueous inactivated antigenic material in an amount sufficient to induce an immune response - up to 100. The group of inventions also includes a method for immune response stimulation, comprising administration of the above preparation.EFFECT: application of this group of inventions allows to stimulate the immune response when using a mixture of fatty acid and fatty acid N,N-dimethylaminopropylamide as an adjuvant.2 cl, 6 tbl
Preparation for application of aspartate and vitamin b12 or biotine for ketone bodies regulation // 2633071
FIELD: pharmacology.SUBSTANCE: compositions (versions) for enteral use for treatment and/or prevention of disturbed ketone and lactate metabolism, i.e. increased concentrations of ketone bodies, lactate and/or other organic acids of a mammal suffering from hyperglycemia after fasting or after eating, resistance to insulin or diabetes, comprising 12-40 wt % of aspartate equivalents in the protein fraction of vegetable and animal proteins in combination with vitamin B12.EFFECT: improved glucose and insulin response in blood, and restoration of the glucose and fatty acid metabolism balance.19 cl, 2 tbl, 4 ex

Cenicriviroc compositions and methods for their production and application // 2633069
FIELD: pharmacology.SUBSTANCE: composition contains Cenicriviroc or its salt and fumaric acid. A method of preparation of the said composition, a pill, a method for preparation of the said pill and a method for treatment of a disease, disorder or condition, comprising administration of a therapeutically effective amount of the said composition or pill, is described.EFFECT: group of inventions can be used to treat viral infection, inflammation, fibrosis or graft-versus-host syndrome.138 cl, 14 dwg, 36 tbl
edicinal for vaginal application, with antiviral, antimicrobial, antifungal, antiprotozoal, antiinfectious, immunomodulating and antiinflammatory action, as ointment, gel, suppository // 2633056
FIELD: pharmacology.SUBSTANCE: medicament is presented comprising active substances, excipients and a consistently-forming base, characterized by comprising fluconazole, metronidazole, alpha- or beta- or gamma-recombinant interferon as active substances, disodium edetate and boric acid as adjuvants, and substances selected from the group: macrogol 400, macrogol 1500, macrogol 4000, vitepsol, glycerin, cocoa butter, paraffin, lanolin, vaseline, acetylphthalyl, GL type solid fat as a consistently forming base, wherein the drug components are in a specific ratio in g per 1 g of the agent.EFFECT: high therapeutic effect ensures rapid substances entry into the blood.1 cl
etabolites (1r-trans)-n-[[2-(2,3-digidro-4-benzofuranyl)cyclopropyl]-methyl]propanamide // 2632889
FIELD: pharmacology.SUBSTANCE: invention relates to metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl) cyclopropyl]methyl]propanamide represented by compounds of formula II or formula III. The invention also relates to a pharmaceutical composition having agonistic activity for melatonin receptors comprising at least one compound selected from the group consisting of a compound of the formula II, a compound of the formula III, and a pharmaceutically acceptable carrier. The compounds of the invention are intended to treat a daily rhythm disturbance or disorder with a daily component, as well as disorders in which a melatonin agonist is indicated.EFFECT: these metabolites are designed to treat disorders in which a melatonin agonist is shown.5 cl, 1 tbl

Sustained-release pharmaceutical composition containing asparaginates // 2632715
FIELD: pharmacology.SUBSTANCE: sustained-release pharmaceutical composition includes potassium asparaginate hemihydrate, magnesium asparaginate dihydrate, matrix-forming polymer, which is an Eudragit polymer, ethyl cellulose, polyvinylpyrrolidone or a combination thereof, a disintegrant such as aerosil, methylcellulose, hydroxypropylmethylcellulose or hydroxypropyl cellulose, an antifriction substance that is talc or starch in the amounts indicated in the claims. The composition is in the form of a solid dosage, preferably in the form of a pill. The composition is characterized by an immediate onset of release and a prolonged, sustained maintenance of the active substances concentration for 12 hours. The pill core can be coated. What is also presented is a method for pharmaceutical composition production.EFFECT: expanded arsenal of drugs used in cardiology and sports medicine, the composition of the invention provides a reduction in the frequency of drug intake, its manufacturing technology is economically advantageous.23 cl, 2 dwg, 1 tbl, 2 ex
Delayed release pharmaceutical composition containing asparaginates // 2632713
FIELD: pharmacology.SUBSTANCE: drug can be used in therapy, in particular in cardiology, and in sports medicine. Preferably, the pharmaceutical composition for oral use in the form of a pill contains hemihydrate, magnesium aspartate dihydrate, microcrystalline cellulose, sodium croscarmellose, aerosil, stearic acid in the potassium asparaginate; the pill shell contains the pH-dependent polymer Eudragit, polyethylene glycol, talc, titanium dioxide. A method for manufacture of a tablet with asparaginates is also described. The composition is characterized by delayed, after 2 hours, release of active ingredients and subsequent rapid release of these active substances in a therapeutically active concentration within 20-30 minutes.EFFECT: reduced side effects on the gastric mucosa.16 cl, 11 dwg, 1 tbl, 11 ex
ethod for reduction of frequency of intraventricular hemorrhage in newborn in case of early preterm delivery, complicated by non-progressing placental abruption // 2632711
FIELD: medicine.SUBSTANCE: from the first minutes, tranexamic acid therapy is provided during admission to the hospital on 25(0)-27(6) weeks of pregnancy for not progressing placental abruption. Hemostatic therapy for patients is performed in the absence of indications for emergency delivery. Hemostatic therapy with tranexamic acid in case of massive (acute) bleeding is prescribed intravenously dropwise for 250-500 mg at a rate of 5-10 mcg/min - 3-4 times a day. The maximum daily dose is 1000-2000 mg/day. Treatment is carried out until the bleeding stops completely, average - 3-4 days. Supportive therapy is prescribed per os 500 mg 3-4 times a day. The maximum daily dose is 1.5-2.0 g, with an average of 3-4 days.EFFECT: decrease in the frequency of intraventricular hemorrhage in a newborn in case early premature delivery at certain time complicated by non-progressive placental abruption.3 ex

ethod for processing tumour cells // 2632429
FIELD: biotechnology.SUBSTANCE: method for processing tumour cells with a composition containing sodium dichloroacetate (DCA) and caffeine sodium benzoate is proposed. The measurement of antitumour activity is based on the distribution of cells by DNA content, which confirms the apoptosis of tumour cells. The effectiveness of the combined effect is assessed by the level of cells with less DNA than the diploid set (sub-G1 population) that result from the fragmentation of the nuclei of apoptotic cells.EFFECT: invention provides high antitumour activity and selectivity of sodium dichloroacetate while reducing toxic effects in non-tumourous cells.8 dwg, 1 ex
Hyposmotic ophthalmic means for ultraviolet crosslinking of thin corneas // 2631604
FIELD: medicine.SUBSTANCE: hypoosmotic ophthalmic means contains riboflavin mononucleotide, hydroxypropylmethylcellulose, tris-(hydroxymethyl)-methylamine, nipagin and purified water. The ingredients are used in the declared ratio.EFFECT: use of the invention provides stroma hydration, necessary increase in the cornea thickness by means of the hypoosmotic properties of the solution, optimal intrastromal concentration of riboflavin, reduced instillations due to stable precorneal film formed by hydroxypropylmethylcellulose introduction.1 ex

Compositions and methods for metabolic pathway modulation // 2631597
FIELD: pharmacology.SUBSTANCE: composition of the invention contains at least 500 mg of leucine and/or at least 200 mg of one or more of its metabolites, wherein one or more leucine metabolites are selected from the group consisting of ketoisocaproic acid (KIC), alphahydroxyisocaproic acid and hydroxymethyl butyrate (HMB), and an antidiabetic agent comprising metformin. The methods of the invention comprise composition administration to a subject.EFFECT: application of the invention can reduce the metformin dose during treatment of metabolic disorders due to the synergistic effect of the composition components.27 cl, 3 tbl, 76 dwg, 10 ex
Analogues of cystamine, used for parkinson's disease treatment // 2630583
FIELD: medicine.SUBSTANCE: application of a therapeutically effective amount of at least one cysteamine analog, namely cysteamine and cystamine or a pharmaceutically acceptable salt thereof, for Parkinson's disease treatment at stage II, III or IV according to the Hoehn and Yahr classification, and wherein the cystamine analog or a pharmaceutically acceptable salt thereof is used as: a) an agent for functional restoration of damaged neurons; and/or b) an agent for the structural repair of damaged neurons. Application of a combination comprising at least one cystamine analogue and cysteine or salts thereof for treatment of Parkinson's disease in a patient with Parkinson's disease symptoms, and application of a pharmaceutical composition comprising at least one cystamine analogue or pharmaceutically acceptable salts thereof and containing cysteine or pharmaceutically acceptable salt thereof for treatment of Parkinson's disease in a patient with Parkinson's disease symptoms, is proposed.EFFECT: functional and structural repair of damaged dopaminergic neurons with cysteamine or cystamine and increased number of nerve cells axons in the damaged areas, cysteine significantly increases cysteamine absorption by the brain.16 cl, 12 dwg
Gel eye drops for chronic and allergic inflammatory diseases treatment // 2629590
FIELD: medicine.SUBSTANCE: gel eye drops include dexamethasone sodium phosphate, a hyaluronic acid source, histidine hydrochloride monohydrate, boric acid, sodium tetraborate, polyethylene glycol, disodium edetate, potassium chloride, sodium chloride and water. The ingredients are used in the declared amounts.EFFECT: use of the invention allows to effectively treat chronic and allergic inflammatory eye diseases of different severity without side effects and allergies.10 ex
ethod for obtaining sulfur-containing organomercury compounds // 2629393
FIELD: pharmacology.SUBSTANCE: method for production of sulfur-containing organomercury compounds of the formula RS-Hg-SR, where R is , or , or , respectively, by reacting an aqueous solution of mercuric diacetate with cysteine, or glutathione, or acetylcysteine, followed by isolation of the product obtained by filtration, washing with water and drying at a room temperature to the constant weight. The reaction is carried out at a molar ratio of mercury and cysteine or glutathione or acetylcysteine of 1:2, and the reaction mixture is kept at a room temperature for 45-90 minutes.EFFECT: increased yield of the desired product with a significant simplification of its production method.3 cl, 4 tbl, 3 ex
Amid derivatives of n-carbamide-substituted amino acids as modulators of formylpeptide receptor-1 (fprl-1) // 2629205
FIELD: chemistry.SUBSTANCE: invention relates to a compoundd represented by the formula , its enantiomers, diastereoisomers or pharmaceutically acceptable salts, which have modulatory activity against N-formylpeptide receptor-1 (FPRL-1). In formula II, a is 1, b is 0 or a is 1, b is 1; R1 is -OH; R2 is C1-8 Alkyl, optionally substituted by C6-10 aryl, amide or heterocycle, wherein the heterocycle is a 3 to 10-membered aromatic ring which contains at least one heteroatom selected from nitrogen, wherein one methylene group in the alkyl can be replaced by sulfur or sulphonyl; R3 is hydrogen or halogen; R4 is hydrogen; R5 is a halogen, -CF3 Or -S (O)nR14; N is 0, 1 or 2; R6 is hydrogen; R7 is hydrogen or halogen; R8 is hydrogen or C1-8 Alkyl; R9 is hydrogen, C1-8 Alkyl, Optionally substituted with a hydroxyl group, or C6-10 aryl; R10 is hydrogen, C1-8 alkyl optionally substituted with a hydroxyl group, or C6-10 aryl; R9a is hydrogen or C1-8 alkyl optionally substituted with a hydroxyl group; R10a is hydrogen or C1-8 alkyl optionally substituted with a hydroxyl group; R14 is CF3 or C1-8 alkyl.EFFECT: increased activity of derivatives.12 cl, 5 tbl, 4 ex
ethod for obtaining of stabilized pharmaceutical composition as aqueous solution // 2629204
FIELD: pharmacology.SUBSTANCE: invention relates to a method for preparation of a stabilized pharmaceutical composition in the form of an aqueous solution which can be used to prepare a drug for intravenous administration containing succinic acid, nicotinamide, inosine and riboflavin mononucleotide sodium as active components and having cytoprotective properties. In the method for preparation of a stabilized pharmaceutical composition in the form of an aqueous solution containing succinic acid, inosine, nicotinamide, riboflavin sodium mononucleotide as active components, by dissolving them in water with subsequent sterilizing filtration, the followin is further added to the composition as a stabilizing agent: one or more pharmaceutically acceptable components selected from the group consisting of sodium hydroxide, trisoxymethylaminomethane (TRIS), ethanolamine, diethanolamine, sodium carbonate, meglumine, to obtain a stable solution with pH in the range of 6.0 to 8.0 in the following ratio, wt %: succinic acid 5.00-12.50; inosine 1.00-2.40; nicotinamide 0.50-1.20; riboflavin mononucleotide sodium 0.10-0.24; stabilizing agent 3.21-51.30; water to 100.0%, and further thermal sterilisation of the solution at a temperature of 100°C and exposure time of 8 min to 116°C and exposure time of 2 min.EFFECT: increased method application safety due to thermal sterilisation.3 cl, 96 ex, 5 tbl
 
2551171.
Up!